ArticleCureus2024
Integrative Management of Bone Deformities in Osteogenesis Imperfecta: A Case Report on Zoledronic Acid and Corrective Osteotomy.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteogenesis imperfecta (OI) is a hereditary genetic condition characterized by brittle bones that are easily broken. Surgical intervention is necessary frequently to treat fractures and deformities in patients diagnosed with OI. In this case, we discuss a case of a nine-year-old male child diagnosed with OI. This boy was previously operated on one year back for a femur fracture with osteotomy and internal fixation with nails, followed by implant removal at a later stage almost one year later. This boy was brought to our hospital with convex deformities of femur and tibia. Upon evaluation and review of this boy's case, the decision was made to administer a zoledronic acid infusion cycle over three days to enhance bone strength. Following this pharmacological therapy, this patient was planned for corrective osteotomy and internal fixation of the femur. This case underscores the complexities of managing OI and also highlights the importance of the therapeutic role of bisphosphonates like zoledronic acid alongside surgical intervention to address these kinds of bony deformities and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.